Frontage gets FDA chiding over Chinese lab

U.S. CRO Frontage has received a Form 483 from the FDA after an inspection of its bioanalytical lab in Shanghai, in-PharmaTechnologist reports. The note is not a full-on FDA warning letter, and the company says the cited problems are minor and "will be sorted without a problem." Report